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Phosphatidylinositol 3-kinase (PI3K) signaling is essential for RAS-driven 
transformation. To directly investigate the role of oncogenic K-Ras binding to PI3K 
in development and tumorigenesis, we generated KrasG12D/+,Y64G/+ mice that express, 
from the endogenous locus, a K-Ras oncoprotein that also contains a “second site” 
amino acid substitution at tyrosine 64 (Y64G) that disrupts the interaction between 
oncogenic K-Ras and PI3K. Surprisingly, KrasG12D,Y64G mice are viable, fertile, and 
phenotypically unremarkable, although they are born at a lower than expected 
Mendelian frequency (26% versus the expected 50% on a C57BL/6 strain 
background). As opposed to the enhanced proliferative rate observed in mouse 
embryonic fibroblasts (MEFs) from K-RasG12D mice, KrasG12D,Y64G MEFs exhibit wild-type 
rates of proliferation. Detailed analysis of the hematopoietic compartment in 
KrasG12D,Y64G mice reveals a reduced proportion of long-term hematopoietic stem 
cells, but no evidence of the aggressive myeloproliferative neoplasm observed 
when a conditional mutant KrasG12D is activated in hematopoietic cells. Consistent 
with these observations, bone marrow cells isolated from K-RasG12D,Y64G mice exhibit 
a normal pattern of myeloid progenitor colony growth in response to cytokine 
stimulation. In contrast to the lack of observed hematologic malignancy, 100% of 
KrasG12D,Y64G mice we examined at 1 year of age showed lung lesions, ultimately 
succumbing to lung tumors with a median survival of 496 days. Despite the 
ubiquitous KrasG12D,Y64G expression, these mice survive longer than models with 
mosaic, adenoviral-Cre recombinase-controlled KrasG12D (median survival of 185 
days). The majority of the lung lesions that arise in KrasG12D, Y64G mice are low grade, 
classified pathologically as atypical lymphoid proliferation or papillary adenomas; 
a few adenocarcinomas are also observed. These studies reinforce the importance 
of oncogenic KRas-mediated activation of PI3K for transformation and 
demonstrate that expressing a Y64G amino acid substitution in the context of 
oncogenic KrasG12D normalizes cell proliferation, rescues embryonic lethality, 
abrogates myeloid disease, and attenuates lung tumorigenesis. Beyond the bone 
marrow and lung, this mutant strain is a potent genetic tool for dissecting the role 
of aberrant PI3K signaling in pancreatic, colon, and other tissues characterized by 
tumors driven by somatic KRAS mutations, and also have implications for treating 
human cancers with KRAS mutations. 
 
